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Abstract
Background: Neuroprotective strategies for prevention of the neuropathological sequelae of traumatic brain
injury (TBI) have largely failed in translation to clinical treatment. Thus, there is a substantial need for further
understanding the molecular mechanisms and pathways which lead to secondary neuronal cell death in the injured
brain. The intracerebral activation of the complement cascade was shown to mediate inflammation and tissue
destruction after TBI. However, the exact pathways of complement activation involved in the induction of
posttraumatic neurodegeneration have not yet been assessed. In the present study, we investigated the role of
the alternative complement activation pathway in contributing to neuronal cell death, based on a standardized TBI
model in mice with targeted deletion of the factor B gene (fB-/-), a "key" component required for activation of
the alternative complement pathway.
Results: After experimental TBI in wild-type (fB+/+) mice, there was a massive time-dependent systemic
complement activation, as determined by enhanced C5a serum levels for up to 7 days. In contrast, the extent of
systemic complement activation was significantly attenuated in fB-/- mice (P < 0.05,fB-/- vs. fB+/+; t = 4 h, 24 h,
and 7 days after TBI). TUNEL histochemistry experiments revealed that posttraumatic neuronal cell death was
clearly reduced for up to 7 days in the injured brain hemispheres of fB-/- mice, compared to fB+/+ littermates.
Furthermore, a strong upregulation of the anti-apoptotic mediator Bcl-2 and downregulation of the pro-apoptotic
Fas receptor was detected in brain homogenates of head-injured fB-/- vs. fB+/+ mice by Western blot analysis.
Conclusion: The alternative pathway of complement activation appears to play a more crucial role in the
pathophysiology of TBI than previously appreciated. This notion is based on the findings of (a) the significant
attenuation of overall complement activation in head-injured fB-/- mice, as determined by a reduction of serum
C5a concentrations to constitutive levels in normal mice, and (b) by a dramatic reduction of TUNEL-positive
neurons in conjunction with an upregulation of Bcl-2 and downregulation of the Fas receptor in head-injured fB-
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BMC Neuroscience 2006, 7:55 http://www.biomedcentral.com/1471-2202/7/55/- mice, compared to fB+/+ littermates. Pharmacological targeting of the alternative complement pathway during
the "time-window of opportunity" after TBI may represent a promising new strategy to be pursued in future
studies.
Background
The high incidence of adverse outcomes after traumatic
brain injury (TBI) has been attributed in large part to sec-
ondary mechanisms of neuronal cell death [1,2]. These
include the induction of neuronal apoptosis and comple-
ment-mediated neuronal cell lysis [3-7]. Recent evidence
suggests that the intracerebral activation of the comple-
ment cascade influences the fate of neurons by other than
just the "classical" neuroinflammation-mediated effects
[8-10]. For example, neuronal apoptosis can be induced
by complement activation products, e.g. by binding of the
anaphylatoxin C5a to its receptor (C5aR/CD88) expressed
on neurons [11-15]. In addition, complement-mediated
neuronal cell lysis can occur through the membrane
attack complex (MAC; C5b-9) following inactivation of
the physiological cellular protection mechanisms against
homologous complement-mediated cell death [16-20].
Insights from recent experimental studies on intracerebral
MAC injection underline the important role of the mem-
brane attack pathway of complement in contributing to
secondary neurodegeneration [21,22]. Posttraumatic
complement activation and tissue deposition of the MAC
were furthermore demonstrated in injured human and
rodent brains by immunohistochemistry [18,23-26]. In
addition, we have reported elevated levels of soluble MAC
in human cerebrospinal fluid (CSF) after severe head
injury [27].
Up to date, most studies which investigated the role of
complement activation in the injured brain have focused
on the effects of the complement cascade at a point where
all three activation pathways converge, i.e. at the level of
C3 or further downstream in the cascade [26,28-33].
Thus, the role which the individual pathways of comple-
ment activation play in the pathophysiology of TBI has
not yet been determined. Recent studies established the
alternative pathway of complement activation as a "key
player" in the pathogenesis of ischemia/reperfusion-
mediated inflammatory diseases outside the CNS [34].
For example, complement activation in renal ischemia/
reperfusion injury was shown to be mediated almost
exclusively by the alternative pathway [34-36]. In clinical
studies on TBI patients, we have reported elevated levels
of the crucial components required for alternative path-
way complement activation, factor B and C3, in the CSF
of severely head-injured patients [37].
Here, we demonstrate for the first time an important role
of the alternative complement pathway in contributing to
posttraumatic neuronal cell death, based on a standard-
ized TBI model in factor B gene-deficient mice.
Results and discussion
Complement activation is attenuated in brain-injured fB-/
- mice
Screening of serum samples from all fB-/- mice and wild-
type littermates (fB+/+) used in the present study revealed
that factor B was only detectable in serum of fB+/+ ani-
mals, but not in the fB-/- mice. These control experiments
were performed to ascertain that the knockout mice are
completely devoid of factor B in serum. An exemplary
Western blot is shown in Fig. 1.
Experimental closed head injury in wild-type C57BL/6
mice resulted in a systemic activation of the complement
cascade, as determined by significantly elevated serum
levels of the complement activation product C5a at all
time-points assessed from 4 hours to 7 days (P < 0.05 vs.
normal mouse serum, unpaired Student's t-test; Fig. 2). In
contrast, anaphylatoxin C5a serum levels were not
induced in fB-/- mice at all corresponding time-points
after head trauma and found to be in a similar range to
baseline levels in normal C57BL/6 or fB-/- mice (P < 0.05
vs. brain-injured fB+/+ mice, unpaired Student's t-test; Fig.
2). The data indicate the lack of C5a increase in sera of fB-
/- mice. It seems likely that this is due to impaired gener-
ation of C5a via the alternative pathway of complement
activation, although accelerated metabolic destruction of
C5a in the absence of factor B cannot be ruled out. These
findings imply that the alternative pathway is the source
for complement activation after brain injury, a notion
which was previously substantiated for other inflamma-
tory diseases outside the CNS, such as rheumatoid arthri-
tis, autoimmune nephritis, and ischemia/reperfusion
injuries [34,38].
Experimental head injury induced mean anaphylatoxin
C5a levels in serum of around 50 ng/ml within 7 days in
wild-type mice (Fig. 2). Serum C5a levels described in the
literature due to triggers for complement activation other
than CNS trauma are in the range of 100 ng/ml, as
described for patients with severe sepsis [39]. With regard
to central nervous system inflammation, we have previ-
ously reported significantly elevated C5a levels in human
CSF of patients with bacterial meningitis (mean levels
around 75 ng/ml), as compared to patients with aseptic/
viral meningitis [40]. C5a levels were not detectable in
normal CSF of n = 66 healthy humans with a lower limitPage 2 of 12
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serum C5a levels detected in brain-injured C57BL/6 mice
in the present study appear to reflect concentrations of
clinical relevance, as far as data derived from an experi-
mental mouse model can be extrapolated to human dis-
ease.
The lack of factor B leads to reduced neuronal cell death 
after head injury
The mortality from brain injury in this model system is
approximately 5–8% within 7 days, as previously reported
[41]). There was no difference in mortality between fB-/-
and fB+/+ mice. As previously described, neuronal cell
death was observed in injured brains of wild-type C57BL/
6 mice for up to 7 days after closed head injury [41]. An
increase in TUNEL-positive cells was detected in the
injured hemispheres of fB+/+ mice within 4 to 24 hours
after trauma, persisting for up to 7 days (Fig. 3and Fig. 4;
panels D & E; whereby E represents a 4-fold magnifica-
tion of D). The nuclear staining with 4',6'-diamino-2-phe-
nylindole (DAPI; panel C) shows the cellular morphology
in adjacent sections to those assessed by TUNEL histo-
chemistry. Neurons were determined as the main TUNEL-
positive cell-type by immunohistochemical staining of
adjacents sections with the specific cell-marker NeuN (Fig.
4, panels A & B whereby B represents a 4-fold magnifica-
tion of A). The staining of astrocytes (anti-GFAP), micro-
glia (anti-CD11b), and endothelial cells (anti-CD144)
revealed that these resident cells in the brain are represent
only a small part of TUNEL-positive cells, e.g. in the
molecular layer of the cortex (Fig. 4). Furthermore, neu-
rons were confirmed as the predominant TUNEL-positive
cell-type by their typical cellular size and morphology (as
opposed to glial cells) and to the typical neuronal layers
of TUNEL-positive cells in the injured cortex (Fig. 4). The
Elevated C5a levels in serum of brain-injured C57BL/6 (fB+/+) mice are significantly attenuated i  factor B gene-deficient (fB-/-) mic  lack ng a func io al alter ative complement path-wayFigur 2
Elevated C5a levels in serum of brain-injured C57BL/
6 (fB+/+) mice are significantly attenuated in factor B 
gene-deficient (fB-/-) mice lacking a functional alter-
native complement pathway. Serum samples from brain-
injured fB+/+ and fB-/- mice of the C57BL/6 strain (n = 6 per 
group and time-point) and from normal C57BL/6 mice (con-
trol; n = 4) and normal fB-/- mice (n = 4) were analyzed by 
ELISA specific for mouse C5a. Data are shown as mean levels 
± SD. *P < 0.05, fB+/+ vs. control and fB+/+ vs. fB-/- mice. 
TBI, traumatic brain injury.
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Screening of serum samples from fB-/- and fB+/+ mice for factor B protein, as shown for an exemplary Western blotFigure 1
Screening of serum samples from fB-/- and fB+/+ mice for factor B protein, as shown for an exemplary West-
ern blot. Samples were run out on SDS-PAGE, transferred to nitrocellulose membranes, and analyzed with a specific mono-
clonal anti-mouse factor B antibody and detection by chemiluminescence (ECL® system, Amersham). A specific 98 kDa band, 
corresponding to murine fB, is detectable in the fB+/+, but not in the fB-/- mice. Each lane is representative of an individual 
mouse. The bottom panel shows equal protein loading in the different bands by ponceau red staining.
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Attenuated neuronal cell death in the injured hemisphere of factor B gene-deficient mice 24 hours after closed head injuryFigure 3
Attenuated neuronal cell death in the injured hemisphere of factor B gene-deficient mice 24 hours after closed 
head injury. Coronal cryosections of the left (injured) hemisphere of wild-type (fB+/+, panels A-E) and factor B knockout 
mice (fB-/-, panels F-J) were analyzed by immunohistochemistry with a specific antibody to the neuronal marker NeuN (A, B, 
F, G) or by TUNEL-histochemistry of adjacent sections (D, E, I, J). The overall cellular morphology of the TUNEL sections is 
revealed by DAPI nuclear stain (C, H). The panels B, E, G, J represent a 4-fold magnification of the respective panels A, D, F, 
I. The evident destruction of the cortical tissue in brain-injured wild-type mice (upper panels) appears to be structurally pre-
served in fB-/- mice (bottom panels). The data shown here are highly reproducible in all tissue sections and animals assessed. 
Original magnifications: 100× (A, C, D, F, H, I), 400× (B, E, G, J).
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Attenuated neuronal cell death in the injured hemisphere of factor B gene-deficient mice 7 days after closed head injuryFigure 4
Attenuated neuronal cell death in the injured hemisphere of factor B gene-deficient mice 7 days after closed 
head injury. Coronal cryosections of the left (injured) hemisphere of wild-type (fB+/+, panels A-E) and factor B knockout 
mice (fB-/-, panels F-J) were analyzed by immunohistochemistry with a specific antibody to the neuronal marker NeuN (A, B, 
F, G) or by TUNEL-histochemistry of adjacent sections (D, E, I, J). The overall cellular morphology of the TUNEL sections is 
revealed by DAPI nuclear stain (C, H). The panels B, E, G, J represent a 4-fold magnification of the respective panels A, D, F, 
I. The data shown here are highly reproducible in all tissue sections and animals assessed. Original magnifications: 100× (A, C, 
D, F, H, I), 400× (B, E, G, J).
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BMC Neuroscience 2006, 7:55 http://www.biomedcentral.com/1471-2202/7/55data shown in figures 3and 4 are highly reproducible in
all tissue sections and animals assessed and are represent-
ative for 2–3 mice of each group (fB+/+ and fB-/-) per
time-point assessed. These findings corroborate previ-
ously published data on neuronal apoptosis in the current
and other experimental TBI models as well as in head-
injured patients [41-45]. In contrast to the extent of neu-
ronal cell death in brain-injured fB+/+ mice, the fB-/- ani-
mals showed a clear reduction in TUNEL-positive neurons
in injured brains from 4 hours to 7 days after trauma (Fig.
3and Fig. 4, panels I & J vs. D & E, respectively). In addi-
tion, the evident cortical tissue destruction in brain-
injured wild-type mice at 24 hours (Fig. 3, upper panels)
appears to be structurally preserved in fB-/- mice (Fig. 3,
bottom panels). TUNEL-positive cells and extent of tissue
destruction were less in the contralateral (right) hemi-
sphere as compared to the injured (left) hemisphere at all
time-points assessed, both in the knockout and the wild-
type mice (data not shown). These findings support the
recently established concept of complement-dependent
regulation of neuronal apoptosis [7,10,15,46] and pro-
mote the in vivo significance of the alternative (factor B-
dependent) pathway of complement activation in regulat-
ing the extent of secondary neurodegeneration after TBI.
This is the first study, to our knowledge, which investi-
gated exclusively the role of the alternative pathway in
contributing to neuropathology after brain injury. The fB-
/- mice have previously been shown to be protected from
experimental demyelination in an animal model of mul-
tiple sclerosis [47]. The studies by Nataf and colleagues
support our present findings in that the genetic deficiency
of factor B, which provokes the complete lack of a func-
tional alternative complement activation pathway, plays
an essential role for neuroprotection in models of autoim-
mune and traumatic CNS injury.
Upregulation of Bcl-2 and downregulation of Fas in injured 
fB-/- brains
Posttraumatic neuronal apoptosis has been shown to be
promoted by the Fas-mediated extrinsic pathway and by a
suppression of the mitochondrial anti-apoptotic mediator
Bcl-2 of the intrinsic pathway of apoptosis [48-54]. By
Western blot analysis, we found a marked upregulation of
protective Bcl-2 protein levels in brain homogenates of
sham-operated and head-injured fB-/- mice at 24 hours –
and to a lesser degree at 7 days – after trauma, compared
to fB+/+ littermates (Fig. 5). No differences in Bcl-2
expression between knockout and wild-type mice was
seen at 4 h after TBI (Fig. 5). Interestingly, sham-operation
alone was a sufficient trigger for inducing Bcl-2 protein
expression in the brain of fB-/- mice within 24 h (Fig. 5).
We have previously reported the phenomenon of
increased intracerebral mediator expression by sham
operation alone (i.e. anesthesia and scalp incision) such
as for the anaphylatoxin C5a receptor (C5aR/CD88) in
sham-operated C57BL/6 mice [13]. In the present study, it
appears that the threshold for induction of Bcl-2 in the
brain of sham-operated knockout mice is lower than in
wild-type mice, thus possibly contributing to increased
intracerebral Bcl-2 levels also in the brain-injured fB-/-
mice. We plan to explore the pharmacological aspects of
this phenomenon in future studies.
With regard to the extrinsic pathway of apoptosis, a
marked downregulation in Fas receptor expression was
seen within 4 hours to 7 days after TBI in fB-/- mice, com-
pared to fB+/+ animals (Fig. 5). Although these data are
not quantitative, the differences in staining intensity of
the 26 kDa (Bcl-2) and 48 kDa bands (Fas) appear more
intense in the brain-injured knockout mice than in the
corresponding wild-type littermates at the above-men-
tioned time-points (Fig. 5). These findings suggest, but do
not prove, an involvement of the alternative pathway of
complement activation in regulating neuronal apoptosis
after TBI by suppression of Bcl-2 and induction of Fas
receptor expression in the injured brain. Both aspects are
critical in the regulation of post-injury neuronal apopto-
sis, as previously determined by other investigators in dif-
ferent model systems [48-50]. An experimental study on a
controlled cortical impact brain injury model demon-
strated that the cortical lesion volume was significantly
reduced in transgenic mice with over-expression of the
Bcl-2 gene by 7 days after trauma, compared to wild-type
littermates [55]. Thus, Bcl-2 was attributed an important
role in the regulation of the mitochondrial (intrinsic)
pathway of apoptosis after TBI [4,53,55,56].
We have recently shown that the pharmacological "pan"-
inhibition of complement activation at the level of the C3
convertases by Crry-Ig, a murine recombinant chimeric
fusion molecule, leads to enhanced intracerebral Bcl-2
gene and protein expression and to increased neuronal
survival in the hippocampus of brain-injured mice [32].
Similar findings were described in a model of murine
autoimmune cerebritis, where the blocking of comple-
ment activation by Crry-Ig resulted in a significant attenu-
ation of neuronal apoptosis [15].
The data from the present study support the biological sig-
nificance of the alternative pathway of complement acti-
vation in contributing to the neuropathological sequelae
of TBI and provide the basis for future pharmacological
studies with selective alternative pathway inhibitors, e.g.
such as factor B antagonists [34,57].
Conclusion
In summary, the present data provide first evidence of a
major role of the alternative pathway of complement acti-
vation in contributing to the overall extent of posttrau-
matic complement activation (C5a generation) and toPage 6 of 12
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Upregulation of Bcl-2 and downregulation of Fas receptor in brains of fB-/- mice after traumatic brain injury (TBI), as deter-min d by Western blot analysisFigure 5
Upregulation of Bcl-2 and downregulation of Fas receptor in brains of fB-/- mice after traumatic brain injury 
(TBI), as determined by Western blot analysis. Homogenized brain tissue specimens from the injured hemispheres of 
sham-operated and head-injured fB+/+ and fB-/- mice were run out on SDS-PAGE, transferred to nitrocellulose membranes, 
and analyzed with specific monoclonal antibodies to Bcl-2, Fas, and β-actin as internal control and detection by chemilumines-
cence assay (ECL® system, Amersham). (A) The visualized 26 kDa band corresponding to mouse Bcl-2 is enhanced in the 
knockout mice at 24 hours, compared to head-injured wild-type littermates. Furthermore, a downregulation in Fas receptor 
staining intensity is obvious in brain-injured knockout mice at all time-points assessed, compared to fB+/+ mice. The exemplary 
blot is representative of three independent experiments. (B) The individual band intensities of the blot shown in panel A were 
quantified by TINA 2.09 software (Raytest, Straubenhardt, Germany) and the data are shown as relative levels to the according 
β-actin band intensity.
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BMC Neuroscience 2006, 7:55 http://www.biomedcentral.com/1471-2202/7/55secondary neuronal cell death after brain injury (TUNEL,
Bcl-2, and Fas data). This is a fairly new and provocative
notion, since all previously published studies on experi-
mental complement inhibition in TBI models have
focussed on interfering with the complement cascade at
the "common junction" level of C3 convertases [26,28-
32] or further downstream in the cascade, e.g. by specific
blocking of anaphylatoxin C5a or its receptor [30]. The
hitherto underestimation of the pathophysiological role
of the alternative complement pathway in the neuropa-
thology of brain injury may be in part due to the histori-
cally established predominant role of the classical
pathway in various neurological diseases [58,59]. How-
ever, the results from the present study imply that these
insights may not necessarily reflect the "true" in vivo sig-
nificance of the alternative complement pathway in a
complex multifactorial neuroinflammatory disease, such
as in the setting of TBI [60]. The fact that elevated factor B
levels are present in the intrathecal compartment of
severely head-injured patients [37] further supports the
concept that the pharmacological targeting of factor B
may present a reasonable basis for future investigations.
Methods
Factor B-/- mice
The genetic knockout mice deficient in factor B (fB-/-)
were previously characterized and shown to have a com-
plete lack of a functional alternative complement pathway
[61]. They were originally created with Sv129 embryonic
stem cells and crossed with C57BL/6 mice prior to expan-
sion of the colony at F1. They were then back-crossed for
more than 10 generations against a pure C57BL/6 back-
ground and found to be grossly indistinguishable from
C57BL/6 mice [35]. Knockout mice and wild-type litter-
mates (fB+/+) were acclimatized several weeks before the
experiments and kept isolated from external influences
during the entire time course of the study. They were bred
in a selective pathogen-free (SPF) environment and stand-
ardized conditions of temperature (21°C), humidity
(60%), light and dark cycles (12:12 h), with food and
water provided ad libitum. Only male mice were used for
this study in order to avoid a bias in gender with regard to
levels of complement activity and to susceptibility to
brain injury which seems to be significantly influenced by
female reproductive hormones [62,63]. All experiments
were performed in compliance with the standards of the
Federation of European Laboratory Animal Science Association
(FELASA) and were approved by the institutional animal
care commitee (Landesamt für Arbeitsschutz, Gesundheitss-
chutz und technische Sicherheit, Berlin, Germany, No.
G0099/03 and No. G0308/04).
Brain injury model
Experimental closed head injury was performed in knock-
out (fB-/-) mice and wild-type littermates (fB+/+) of the
C57BL/6 strain (n = 6 per group and time-point) using a
standardized weight-drop device, as previously described
[13,41,64-66]. In brief, after induction of isoflurane
anesthesia, the skull was exposed by a midline longitudi-
nal scalp incision. A 333 g weight was dropped on the
fixed skull from a height of 2 cm, resulting in a focal blunt
injury to the left hemisphere. After trauma, the mice
received supporting oxygenation with 100% O2 until fully
awake and were then brought back to their cages. At
defined time-points (t = 4 h, 24 h, and 7 days), mice were
euthanized and brain hemispheres were extracted for
analysis by immunohistochemistry, TUNEL histochemis-
try, and SDS-PAGE/Western blot analysis. In addition,
serum samples were collected for determination of com-
plement anaphylatoxin C5a levels by ELISA and Western
blot analysis of Bcl-2 (see below).
Sham-operated mice were kept under identical conditions
as the trauma group and underwent the same procedures
(anesthesia and scalp incision) except that no head injury
was applied.
ELISA for mouse C5a
For determination of complement anaphylatoxin C5a lev-
els in serum samples of head-injured and normal C57BL/
6 control mice, we used an ELISA developed in the labo-
ratory of Dr. P.A. Ward (Ann Arbor, MI, USA), as previ-
ously described [67]. In brief, ELISA plates (Immulon
4HBX, Thermo Labsystems, Milford, MA, USA) were
coated with purified monoclonal anti-mouse C5a IgG (5
μg/ml, BD Pharmingen, San Diego, CA, USA). This cap-
ture antibody recognizes both C5a and C5a-desArg, but
not the precursor molecule C5. After blocking of non-spe-
cific binding sites with 1% milk (Roth, Karlsruhe, Ger-
many) in PBS (Gibco-Invitrogen, Carlsbad, CA, USA)
containing 0.05% TWEEN 20 (Sigma-Aldrich, St. Louis,
MO, USA), the plate was coated with 100 μl serum diluted
1:20 (in 0.1% milk in PBS contaning 0.05% TWEEN) and
murine recombinant mouse C5a at defined concentra-
tions for establishing the standard curve. After incubation
and subsequent washing steps, biotinylated monoclonal
anti-mouse C5a antibody was added at 500 ng/ml (BD
Pharmingen) followed by washing steps and incubation
with streptavidin-peroxidase at 400 ng/ml (Sigma). For
colorimetric reaction, the substrate (0.4 mg/ml OPD with
0,4 mg/ml urea hydrogen peroxide in 0.05 M phosphate
citrate buffer; Sigma) was added and the color reaction
was stopped with 3 M sulfuric acid. The absorbance was
read at 490 nm ("SpectraMax 190" reader, Molecular
Devices, Sunnyvale, CA, USA. All samples were analyzed
in duplicate wells and results were calculated from the
means of duplicate sample analysis. The standard curve
was linear from 50 ng/ml to 0.1 ng/ml which represents
the lower limit of detection of this assay.Page 8 of 12
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All mice used in this study were screened by Western blot
analysis for the presence of factor B in serum, as an inter-
nal quality control (Fig. 1). The protein levels of the mito-
chondrial anti-apoptotic mediator Bcl-2 and of the pro-
apoptotic Fas receptor were determined in homogenized
mouse brains and matched serum samples at 4 h, 24 h
and 7d following head injury or sham operation in fB-/-
and fB+/+ mice. The Western blot technique was previ-
ously described [32]. Briefly, mouse brains were extracted
under anesthesia, separated into left and right hemi-
spheres, and immediately homogenized in lysis buffer
(Sigma) containing 100 mM TRIS-HCl (pH 7.5), 150 mM
NaCl, 0.5% sodium dodecyl sulfate (SDS), 0.5% Nonidet
P-40, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 5 μg/ml
pepstatin, 1 mM phenyl-methyl-sulfonyl fluoride in
deionized water, using an Ultra Turrax Homogenizer®
(IKA Werke, Staufen, Germany). After 15 min centrifuga-
tion at 13,000 × g, the protein content of the supernatants
was determined by commercially available colorimetric
protein assay ("BCA Protein Assay", Pierce/Perbio Sci-
ence, Bonn, Germany). A 60 μg sample of total protein
was denatured in loading buffer and separated under
reducing conditions on 12% SDS-polyacrylamide gels in
parallel with a broad range prestained SDS-PAGE protein
standard (Bio-Rad, Munich, Germany). Proteins were
then transferred to Protran BA 83 nitrocellulose mem-
branes (Schleicher & Schuell, Dassel, Germany) by elec-
troblotting (Bio-Rad). Equal transfer of protein to the
blotting membrane was confirmed by ponceau red stain-
ing (Sigma). The blots were blocked overnight and then
incubated with either monoclonal anti-mouse Bcl-2
(Santa Cruz Biotechnology, Heidelberg, Germany),
diluted 1:500, polyclonal rabbit anti-mouse Fas (clone A-
20, Santa Cruz), diluted 1:200, polyclonal chicken anti-
mouse anti-factor B, diluted 1:8,000 (kindly provided by
Dr. Scott R. Barnum, University of Alabama at Birming-
ham, AL, USA) as primary antibodies, and with a mono-
cloncal anti-β-actin antibody (clone AC-15, Sigma)
diluted 1:10,000, as internal control for ascertaining equal
loading of the bands. After incubation with peroxidase-
labelled secondary antibodies (Dako, Hamburg, Ger-
many, and Santa Cruz Biotechnology, Heidelberg, Ger-
many), diluted 1:5,000, antibody binding was visualized
by a non-radioactive chemiluminescence technique using
a commercially available ECL® Western blotting kit (Amer-
sham Pharmacia Biotech, Freiburg, Germany). A semi-
quantitative analysis of the individual band intensities
was performed by scanning the films (hp Scanjet 5530,
Hewlett-Packard, Böblingen, Germany) followed by
quantification using the TINA 2.09 software (Raytest,
Straubenhardt, Germany). The data are presented in his-
tograms as relative levels to the according β-actin band
intensity.
Immunohistochemistry
For assessment of neuronal morphology, integrity, and
apoptosis, extracted mouse brains were snap-frozen in liq-
uid nitrogen, embedded in OCT compound (Sakura Fine-
tek, Torrance, CA) and stored at -80°C until used for
analysis. Six to eight-micrometer thick coronal tissue sec-
tions were cut with a cryostat at -20°C. For immunohisto-
chemistry, slides were fixed in acetone and then analyzed
by a standard biotin/avidin/peroxidase technique with
DAB-tetrahydrochloride as chromogen (Vector, Burlin-
game, CA), as previously described [13,32]. The following
primary antibodies were used as cell-markers: mono-
clonal anti-NeuN, at a titrated dilution of 1:2,000
(Chemicon, Hampshire, UK) for neurons; polyclonal rab-
bit anti-GFAP, 1:100 (Shandon Immunon, Pittsburgh, PA,
USA) for astrocytes; monoclonal rat anti-CD11b, 1:100,
(Accurate Chemical, Westbury, NY, USA) for microglia;
polyclonal goat-anti CD144, 1:200 (Santa Cruz) for
endothelial cells. Non-immunized IgG (Vector) was used
as negative control at equal dilutions as the omitted spe-
cific antibody.
To determine the extent of intracerebral neuronal cell
death, TUNEL histochemistry was performed using a "Flu-
orescein In Situ Cell Death Detection Kit" (Roche Diag-
nostics GmbH, Mannheim, Germany), according to the
manufacturer's instructions, as previously described [41].
Briefly, slides were dried for 30 min followed by fixation
in 10% formalin solution at RT. After washing in PBS
(three times for 3 min), sections were incubated in ice-
cold ethanol-acetic acid solution (2:1) for 5 min at -20°C.
Thereafter, they were washed in PBS and incubated in a
permeabilization solution with 3% Triton X-100 in PBS
for 60 min at RT, then incubated with the TdT enzyme in
a reaction buffer containing fluorescein-dUTP for 90 min
at 37°C. Negative control was performed using only the
reaction buffer without TdT enzyme. Positive controls
were performed by digesting equal brain sections with
DNase grade I solution (500 U/ml; Roche) for 20 min at
RT and always kept separate from the other samples there-
after. After labelling, the sections were washed again in
PBS and to visualize the unstained (TUNEL-negative)
cells, the sections were covered with Vectashield® mount-
ing medium for fluorescence with DAPI (Vector). All sam-
ples were evaluated immediately after staining using an
Axioskop 40 fluorescence microscope (Zeiss, Germany) at
460 nm for DAPI and 520 nm for TUNEL fluorescence
and analyzed by Alpha digi doc 1201 software (Alpha
Innotech, San Leandro, CA, USA).
Statistical analysis
Statistical analysis was performed using commercially
available software (SPSS 9.0 for Windows™). Differences
in complement C5a levels in serum of fB-/- and fB+/+Page 9 of 12
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P-value < 0.05 was considered statistically significant.
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